Income Statement

v3.24.4
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Revenue    
Revenue $ 4,356,515 $ 8,274,690
Cost of Revenue 1,426,447 2,845,201
Gross profit 2,930,068 5,429,489
Operating expenses    
Sales and marketing 1,041,425 1,816,702
Distribution costs 1,455,725 2,131,892
General and administrative expenses 1,367,690 1,578,350
Share-based compensation 141,298 421,887
Amortization of acquired intangible assets 19,190 658,858
Depreciation 239,905 277,613
Total operating expenses 4,265,233 6,885,302
Loss from operations (1,335,165) (1,455,813)
Other 0 (9,808)
Interest expense, net (290,412) (843,475)
Other expense, net (290,412) (853,283)
Loss on operations before income tax (1,625,577) (2,309,096)
Income tax benefit 0 472,367
Total Income Taxn Expense Benefit 0 472,367
Net loss from continuing operations (1,625,577) (1,836,729)
Gain from the sale of Interactive Offers 0 380,624
Total Gain from the sale of Interactive Offers 0 380,624
Income (loss) on discontinued operations    
Interactive offers 0 (193,040)
VitaMedica 0 69,406
E-core 0 224,351
Income discontinued operations 0 100,717
Net loss attributable to Upexi, Inc. $ (1,625,577) $ (1,355,388)
Basic income (loss) per share:    
Loss per share from continuing operations $ (1.55) $ (1.81)
Income per share from discontinued operations 0 0.10
Total income (loss) per share attributable to Upexi shareholders (1.55) (1.34)
Diluted income (loss) per share:    
Loss per share from continuing operations (1.55) (1.81)
Income per share from discontinued operations 0 0.10
Total loss per share attributable to Upexi shareholders $ (1.55) $ (1.34)
Basic weighted average shares outstanding 1,045,429 1,012,231
Fully diluted weighted average shares outstanding 1,045,429 1,012,231

Source